Copyright
©The Author(s) 2021.
World J Gastroenterol. Jul 14, 2021; 27(26): 4182-4193
Published online Jul 14, 2021. doi: 10.3748/wjg.v27.i26.4182
Published online Jul 14, 2021. doi: 10.3748/wjg.v27.i26.4182
Societies | Antivirals | HBV-DNA level | When to start treatment | When to stop treatment |
American Association for the Study of Liver Diseases[25] | Tenofovir disoproxil fumarate | > 2 × 105 IU/mL | 28-32 wk | At birth to 3 mo |
European Association for the Study of the Liver[24] | Tenofovir disoproxil fumarate | > 2 × 105 IU/mL | 24-28 wk | Up to 12 wk after delivery |
Asian Pacific Association for the Study of the Liver[70] | Tenofovir disoproxil fumarate, telbivudine | > 106-7 IU/mL | 28-32 wk | At delivery |
Chinese Medical Association[71] | Tenofovir disoproxil fumarate, telbivudine, lamivudine | > 2 × 106 IU/mL | 24-28 wk | At delivery |
National Institute for Health and Care Excellence[72] | Tenofovir disoproxil fumarate | > 107 IU/mL | 3rd trimester | 4-12 wk after birth |
- Citation: Veronese P, Dodi I, Esposito S, Indolfi G. Prevention of vertical transmission of hepatitis B virus infection. World J Gastroenterol 2021; 27(26): 4182-4193
- URL: https://www.wjgnet.com/1007-9327/full/v27/i26/4182.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i26.4182